Fig. 6

Association of the L-score with patient response to immunotherapy in lung cancer. The Prat and Banchereau datasets [43, 47] were used in this analysis, and patients were divided into two groups based on their response to immunotherapy. Lung adenocarcinoma patients were separated into responders and non-responders in the Prat cohort [43]. Responders include 1 patient with complete response (CR), 5 with partial response (PR), and 7 with stable disease (SD). Non-responders are 9 patients with progressive disease (PD). In the Banchereau cohort [47], non-small cell lung cancer patients were divided into two groups: 37 patients with CR and 44 patients with other responses—10 with PR, 33 with SD, and 1 with PD. A Responders (1CR + 5PR + 7SD) showed significantly higher L-scores than non-responders (9PD) in the Prat cohort [43]. B Responders (37CR) showed significantly higher L-scores than non-responders (10PR + 33SD + 1PD) in the Banchereau cohort [47]. Of note, the responder/non-responder groups were defined differently between the two datasets in order to balance group sizes. C The association of the L-score with patient response in Banchereau cohort [47] patients with no PD-L1 protein expression in tumor or immune cells. D Receiver operating characteristic (ROC) curves with the L-score as a predictor of patient response. CR complete response, PR partial response, SD stable disease, PD progressive disease, tPD-L1 PD-L1 protein expression in tumor cells, iPD-L1 PD-L1 protein expression in immune cells